

Freedom of Information Request - FOI2024/313

Thank you for your Freedom of Information request.

How many patients were treated in August 2024 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olumiant)
- Dupilumab (Dupixent)
- Lebrikizumab (Ebglyss)
- Omalizumab (Xolair)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)

I have considered your request and have set out the Trust's response below:

Description	Patient Count
Abrocitinib (Cibinqo)	0
Baricitinib (Olumiant)	Less than 6*
Dupilumab (Dupixent)	14
Lebrikizumab (Ebglyss)	0
Omalizumab (Xolair)	Less than 6*
Tralokinumab (Adtralza)	0
Upadacitinib (Rinvoq)	Less than 6*

* Please note that the exact number of patients has been withheld and instead a range of below 6 has been provided, as this relates to a low number. Statistically low information can potentially identify individuals' data, especially due to the rural nature and low population of the county. It would be, in my view, possible to identify them if this data were to be provided to you. The data therefore consists of personal data and as such has been withheld under Section 40(2) of the Freedom of Information Act 2000.

Yours sincerely,

Freedom of Information Officer